Short communicationCirculating innate lymphoid cells are unchanged in response to DAC HYP therapy

- We investigated the impact of daclizumab on circulating innate lymphoid cells in MS patients.
- Daclizumab therapy resulted in increased percentage and number of CD56bright NK cells.
- Daclizumab therapy resulted in increased percentage and number of CD56hiCD16int transitional NK cells.
- No significant changes in total ILCs or ILC subpopulations were observed after daclizumab treatment.

Innate lymphoid cells (ILCs) play an important role in immunity, inflammation, and tissue remodeling and their dysregulation is implicated in autoimmune and inflammatory disorders. We analyzed the impact of daclizumab, a humanized monoclonal anti-CD25 antibody, on circulating natural killer (NK) cells and ILCs in a cohort of multiple sclerosis patients. An increase in CD56bright NK cells and CD56hiCD16intermediate transitional NK cells was observed. No significant change in total ILCs or major ILC subpopulations was observed. These results refine our understanding of the impact of daclizumab on innate lymphoid cell populations.